Publications by Suzanne Kyle - ePrints

Browsing publications by Suzanne Kyle.

Newcastle Authors	Title	Year
Dr Celine Cano Professor Jane Endicott Dr Ian Hardcastle Dr Claire Jennings Suzanne Kyle et al.	Discovery of ASTX295, a potent, next-generation small molecule antagonist of MDM2 with differentiated pharmacokinetic profile	2024
Dr Elaine Willmore Suzanne Kyle Dr Yan Zhao Huw Thomas Dr Kenneth Rankin et al.	Targeting the MDM2-p53 interaction: Time- and concentration-dependent studies in tumor and normal human bone marrow cells reveal strategies for an enhanced therapeutic index	2024
Dr Catherine Willoughby Huw Thomas Dr Elaine Willmore Suzanne Kyle Dr Anita Wittner et al.	Selective DNA-PKcs Inhibition Extends the Therapeutic Index of Localized Radiotherapy and Chemotherapy	2019
Carlo Bawn Dr Martin Galler Huw Thomas Suzanne Kyle Professor Nicola Curtin et al.	PARP inhibitor rucaparib induces changes in NAD levels in cells and liver tissues as assessed by MRS	2017
James Murray Huw Thomas Philip Berry Suzanne Kyle Dr Miranda Patterson et al.	Tumour cell retention of rucaparib, sustained PARP inhibition and efficacy of weekly as well as daily schedules	2014
Michael Batey Dr Yan Zhao Suzanne Kyle Professor Herbie Newell Professor Nicola Curtin et al.	Preclinical Evaluation of a Novel ATM Inhibitor, KU59403, In Vitro and In Vivo in p53 Functional and Dysfunctional Models of Human Cancer	2013
Dr Emma Haagensen Suzanne Kyle Dr Gary Beale Dr Ross Maxwell Professor Herbie Newell et al.	The synergistic interaction of MEK and PI3K inhibitors is modulated by mTOR inhibition	2012
Huw Thomas Suzanne Kyle Ivanda Pavlovska Professor Nicola Curtin	The Clinically Active PARP Inhibitor AG014699 Ameliorates Cardiotoxicity but Does Not Enhance the Efficacy of Doxorubicin, despite Improving Tumor Perfusion and Radiation Response in Mice	2011
Dr Yvette Drew Dr Evan Mulligan Wan Vong Huw Thomas Suzanne Kyle et al.	Therapeutic Potential of Poly(ADP-ribose) Polymerase Inhibitor AG014699 in Human Cancers With Mutated or Methylated BRCA1 or BRCA2	2011
Huw Thomas Suzanne Kyle Rafal Zur Dr Evan Mulligan Professor Nicola Curtin et al.	6-Thioguanine Selectively Kills BRCA2-Defective Tumors and Overcomes PARP Inhibitor Resistance	2010
Dr Asima Mukhopadhyay Dr Ahmed Elattar Dr Aiste McCormick Sarah Wilkinson Dr Yvette Drew et al.	Development of a functional assay for homologous recombination status in primary cultures of epithelial ovarian tumor and correlation with sensitivity to poly(ADP-ribose) polymerase inhibitors	2010
Huw Thomas Suzanne Kyle Tim Robson Professor Nicola Curtin	Vasoactivity of AG014699, a Clinically Active Small Molecule Inhibitor of Poly(ADP-ribose) Polymerase: a Contributory Factor to Chemopotentiation In vivo?	2009
Suzanne Kyle Huw Thomas Dr Jane Mitchell Professor Nicola Curtin	Exploiting the Achilles heel of cancer: the therapeutic potential of poly(ADP-ribose) polymerase inhibitors in BRCA2-defective cancer	2008
Dr Yvette Drew Suzanne Kyle Professor Richard Edmondson Professor Ruth Plummer Professor Nicola Curtin et al.	Investigating DNA double strand break formation and repair in response to the PARP inhibitor AG014699 in cell lines defective in Homologous Recombination: a role for PARP inhibitors in sporadic cancers? [abstract]	2008
Huw Thomas Dr Christopher Calabrese Michael Batey Suzanne Kyle Professor Herbie Newell et al.	Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial	2007
Huw Thomas Kathleen Parker Suzanne Kyle Professor Nicola Curtin	Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase	2005
Dr Christopher Calabrese Michael Batey Professor Alan Calvert Professor barbara Durkacz Suzanne Kyle et al.	Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361	2004
Dr Christopher Calabrese Professor Nicola Curtin Suzanne Kyle Huw Thomas Lan Wang et al.	Design, synthesis, and evaluation of 3,4-dihydro-2H-[1,4]diazepino[6,7,1- hi]indol-1-ones as inhibitors of poly(ADP-ribose) polymerase	2004
Professor Nicola Curtin Lan Wang Suzanne Kyle Dr Christine Arris Professor barbara Durkacz et al.	Novel Poly(ADP-ribose) Polymerase-1 Inhibitor, AG14361, Restores Sensitivity to Temozolomide in Mismatch Repair-Deficient Cells	2004
Professor Nicola Curtin Emeritus Professor Bernard Golding Suzanne Kyle Professor Roger Griffin	Potentiation of cytotoxic drug activity in human tumour cell lines, by amine-substituted 2-arylbenzimidazole-4-carboxamide PARP-1 inhibitors	2004
Dr Christopher Calabrese Michael Batey Huw Thomas Professor barbara Durkacz Lan Wang et al.	Identification of potent nontoxic poly(ADP-ribose) polymerase-1 inhibitors: Chemopotentiation and pharmacological studies	2003
Dr Christopher Calabrese Professor Nicola Curtin Suzanne Kyle Huw Thomas Lan Wang et al.	Novel tricyclic poly(ADP-ribose) polymerase-1 inhibitors with potent anticancer chemopotentiating activity: Design, synthesis, and X-ray cocrystal structure	2002
Professor Nicola Curtin Dr Stephen Barton Michael Batey Dr Christopher Calabrese Professor Alan Calvert et al.	Anti-cancer chemosensitization in vitro and in vivo by a novel potent poly(ADP-ribose) polymerase (PARP1) inhibitor, TBI-361.	2001
Professor Nicola Curtin Professor Alan Calvert Professor barbara Durkacz Professor Roger Griffin Emeritus Professor Bernard Golding et al.	Chemopotentiation studies with two classes of potent (polyADP-ribose) polymerase (PARP) inhibitors in human lung and colon carcinoma cell lines.	2000
Dr Christopher Calabrese Professor Nicola Curtin Michael Batey Huw Thomas Suzanne Kyle et al.	Design and evaluation of novel potent inhibitors of poly (ADP-ribose) polymerase	2000
Suzanne Kyle Professor barbara Durkacz	Mechanisms of enhancement of cytotoxicity in etoposide and ionising radiation-treated cells by the protein kinase inhibitor wortmannin	2000
Lan Wang Suzanne Kyle Alex White Professor Alan Calvert Professor Nicola Curtin et al.	Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines	2000
Suzanne Kyle Professor barbara Durkacz	Cytotoxic mechanism of the protein kinase inhibitor wortmannin in ionising radiation and etoposide treated cells	1999
Suzanne Kyle Professor barbara Durkacz	Interactive effects of inhibitors of poly(ADP-ribose) polymerase and DNA-dependent protein kinase on cellular responses to DNA damage	1999
Professor Nicola Curtin Suzanne Kyle Lan Wang Professor barbara Durkacz Professor Roger Griffin et al.	Potentiation of temozolomide and topotecan growth inhibition by novel potent benzimidazole poly(ADP-ribose) polymerase (PARP) inhibitors	1999
Suzanne Kyle Professor barbara Durkacz	Low nicotinamide mononucleotide adenylyltransferase activity in a tiazofurin-resistant cell line: Effects on NAD metabolism and DNA repair	1997
Suzanne Kyle Professor barbara Durkacz	Wortmannin is a potent inhibitor of DNA double strand break but not single strand break repair in Chinese hamster ovary cells	1996